Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 6:37 p.m.

    📋 Phio Pharmaceuticals Corp. (PHIO) - Clinical Trial Update

    Filing Date: 2026-01-20

    Accepted: 2026-01-20 09:33:00

    Event Type: Clinical Trial Update

    Event Details:

    Phio Pharmaceuticals Corp. (PHIO) Announces Clinical Trial Update Phio Pharmaceuticals Corp. (PHIO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Clinical Stage: clinical trial
    • Collaboration: INTASYL

    🔬 Clinical Development Pipeline (Phio Pharmaceuticals Corp.):

    Product Type Development Stage Therapeutic Area Source
    Placebo BIOLOGICAL Phase PHASE2 Plantar Fasciitis ClinicalTrials.gov
    Collagenase Clostridium Histolyticum (CCH) BIOLOGICAL Phase PHASE2 Plantar Fasciitis ClinicalTrials.gov
    STA-4783 DRUG Phase PHASE2 Soft Tissue Sarcoma ClinicalTrials.gov
    Epoetin alfa DRUG Approved HIV Infections ClinicalTrials.gov
    STA-5326 DRUG Phase PHASE1 Crohn's Disease ClinicalTrials.gov
    STA-5326 mesylate DRUG Phase PHASE2 Crohn's Disease ClinicalTrials.gov
    STA-5312 DRUG Phase PHASE1 Hematological Malignancies ClinicalTrials.gov
    STA 4783 DRUG Phase PHASE1 Stage IIIB Non-Small Cell Lung Cancer ClinicalTrials.gov
    Carboplatin DRUG Phase PHASE1 Stage IIIB Non-Small Cell Lung Cancer ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE1 Stage IIIB Non-Small Cell Lung Cancer ClinicalTrials.gov
    Elesclomol Sodium DRUG Phase PHASE1 Metastatic Solid Tumors ClinicalTrials.gov
    Cysteamine bitartrate DRUG Approved Cystinosis ClinicalTrials.gov
    STA 5326 mesylate DRUG Phase PHASE2 Active, Moderate to Severe Rheumatoid Arthritis ClinicalTrials.gov
    STA 9090 (ganetespib) DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov
    STA-9090 DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    capecitabine + ganetespib DRUG Phase PHASE1 Rectal Cancer ClinicalTrials.gov
    RXI-109 DRUG Phase PHASE2 Keloid ClinicalTrials.gov
    Combination of ganetespib and docetaxel DRUG Phase PHASE2 Non-small Cell Lung Cancer Stage IIIB ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE2 Non-small Cell Lung Cancer Stage IIIB ClinicalTrials.gov
    STA-9090 (ganetespib) with Docetaxel DRUG Phase PHASE1 Solid Tumor Malignancies ClinicalTrials.gov
    Ganetespib DRUG Phase PHASE3 Non-Small-Cell Lung Adenocarcinoma ClinicalTrials.gov
    Elesclomol (STA-4783) DRUG Phase PHASE3 Melanoma ClinicalTrials.gov
    Cysteamine DRUG Phase PHASE1 Fatty Liver ClinicalTrials.gov
    STA-9090 (ganetespib) DRUG Phase PHASE1 AML ClinicalTrials.gov
    Laboratory Biomarker Analysis OTHER Phase PHASE1 Stage I Hypopharyngeal Squamous Cell Carcinoma ClinicalTrials.gov
    Therapeutic Conventional Surgery PROCEDURE Phase PHASE1 Stage I Hypopharyngeal Squamous Cell Carcinoma ClinicalTrials.gov
    STA 9090 DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    STA-4783/paclitaxel DRUG Phase PHASE1 Neoplasms ClinicalTrials.gov
    Dexamethasone DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Bortezomib DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Procrit (epoetin alfa) DRUG Phase PHASE3 Gastrointestinal Cancer ClinicalTrials.gov
    Doxorubicin DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    pertuzumab BIOLOGICAL Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    trastuzumab BIOLOGICAL Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    Sirolimus DRUG Phase PHASE1 Malignant Peripheral Nerve Sheath Tumors (MPNST) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Phio Pharmaceuticals Corp.
    • Ticker Symbol: PHIO

Search

News categories